Evidence map›Paper›PMID 39755982›Full record

ArticleEuropean journal of epidemiology2025

The Stockholm early detection of cancer study (STEADY-CAN): rationale, design, data collection, and baseline characteristics for 2.7 million participants.

Elinor Nemlander, Eliya Abedi, Per Ljungman, Jan Hasselström, Axel C Carlsson, Andreas Rosenblad

Abstract read
In one paragraph

Article in European journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elinor NemlanderDepartment of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden. elinor.nemlander@ki.se.ORCID http://orcid.org/0000-0001-9589-4681
Eliya AbediDepartment of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-6177-4136
Per LjungmanDepartment of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Centre, Karolinska University Hospital, and Division of Haematology, Department of Medicine Huddinge,, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-8281-3245
Jan HasselströmDepartment of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9521-2345
Axel C CarlssonDepartment of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-6113-0472
Andreas RosenbladDepartment of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-3691-8326

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Stockholm Early Detection of Cancer Study (STEADY-CAN) cohort was established to investigate strategies for early cancer detection in a population-based context within Stockholm County, the capital region of Sweden. Utilising real-world data to explore cancer-related healthcare patterns and outcomes, the cohort links extensive clinical and laboratory data from both inpatient and outpatient care in the region. The dataset includes demographic information, detailed diagnostic codes, laboratory results, prescribed medications, and healthcare utilisation data. Since its inception, STEADY-CAN has collected longitudinal data on 2,732,005 individuals aged ≥ 18 years old living in or having access to health care in Stockholm County during the years 2011-2021. Focusing on cancer, the cohort includes 140,042 (5.1%) individuals with incident cancer and a control group of 2,591,963 (94.9%) cancer-free individuals. The cohort's diverse adult population enables robust analyses of early symptom detection, incidental findings, and the impact of comorbidities on cancer diagnoses. Utilizing the wide range of available laboratory data and clinical variables allow for advanced statistical analyses and adjustments for important confounding factors. The cohort's primary focus is to improve understanding of the early diagnostic phase of cancer, offering a crucial resource for studying cancer detection in clinical practice. Its comprehensive data collection provides unique opportunities for research into comorbidities and cancer outcomes, making the cohort a useful resource for ongoing cancer surveillance and public health strategies. The present study gives a detailed description of the rationale for creating the STEADY-CAN cohort, its design, the data collection procedure, and baseline characteristics of collected data.

Indexed as

Early Detection of CancerNeoplasmsAdolescentAdultAgedAged, 80 and overCohort StudiesData CollectionFemaleHumansMaleMiddle AgedResearch DesignSwedenYoung AdultAnaemiaCancerCohort studyLaboratory testsPrimary careReal world data

Identifiers

PMID39755982
PMCPMC11799118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.